as of 12-02-2025 4:00pm EST
IRIDEX Corp is involved in the business of developing, manufacturing, and marketing laser-based medical systems, delivery devices, and consumable instrumentation for ophthalmology. Its products include Lasers, Laser delivery devices, Glaucoma devices, Retinal surgical instruments, and Veterinary and ENT products. The firm also powers its products with its proprietary Micropulse technology. The company operates in only one reportable segment, Ophthalmology. It derives revenues from the sale of consoles, delivery devices, consumables, services, and support activities. The geographical segments of the company include the United States, which drives maximum revenue, Europe, and the Americas, excluding the U.S. and Asia/Pacific Rim.
| Founded: | 1989 | Country: | United States |
| Employees: | N/A | City: | MOUNTAIN VIEW |
| Market Cap: | 20.2M | IPO Year: | 1996 |
| Target Price: | N/A | AVG Volume (30 days): | 105.3K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.30 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.78 - $1.95 | Next Earning Date: | 11-11-2025 |
| Revenue: | $50,647,000 | Revenue Growth: | 4.58% |
| Revenue Growth (this year): | 9.61% | Revenue Growth (next year): | N/A |
Chief Financial Officer
Avg Cost/Share
$0.96
Shares
5,760
Total Value
$5,529.60
Owned After
88,736
SEC Form 4
Chief Financial Officer
Avg Cost/Share
$0.96
Shares
1,000
Total Value
$960.00
Owned After
88,736
SEC Form 4
Chief Financial Officer
Avg Cost/Share
$0.94
Shares
2,133
Total Value
$2,005.02
Owned After
88,736
SEC Form 4
Chief Financial Officer
Avg Cost/Share
$0.96
Shares
3,124
Total Value
$2,998.76
Owned After
88,736
Director
Avg Cost/Share
$0.97
Shares
21,843
Total Value
$21,087.23
Owned After
250,674
SEC Form 4
Chief Financial Officer
Avg Cost/Share
$0.88
Shares
14,769
Total Value
$12,996.72
Owned After
88,736
SEC Form 4
Director
Avg Cost/Share
$0.97
Shares
28,157
Total Value
$27,244.71
Owned After
250,674
SEC Form 4
Chief Financial Officer
Avg Cost/Share
$1.37
Shares
1,450
Total Value
$1,974.50
Owned After
88,736
Chief Financial Officer
Avg Cost/Share
$1.35
Shares
1,250
Total Value
$1,682.20
Owned After
88,736
Chief Financial Officer
Avg Cost/Share
$1.35
Shares
1,500
Total Value
$2,010.00
Owned After
88,736
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Dizon Romeo R | IRIX | Chief Financial Officer | Nov 20, 2025 | Buy | $0.96 | 5,760 | $5,529.60 | 88,736 | |
| Dizon Romeo R | IRIX | Chief Financial Officer | Nov 19, 2025 | Buy | $0.96 | 1,000 | $960.00 | 88,736 | |
| Dizon Romeo R | IRIX | Chief Financial Officer | Nov 18, 2025 | Buy | $0.94 | 2,133 | $2,005.02 | 88,736 | |
| Dizon Romeo R | IRIX | Chief Financial Officer | Nov 17, 2025 | Buy | $0.96 | 3,124 | $2,998.76 | 88,736 | |
| MOORE WILLIAM M | IRIX | Director | Nov 17, 2025 | Buy | $0.97 | 21,843 | $21,087.23 | 250,674 | |
| Dizon Romeo R | IRIX | Chief Financial Officer | Nov 14, 2025 | Buy | $0.88 | 14,769 | $12,996.72 | 88,736 | |
| MOORE WILLIAM M | IRIX | Director | Nov 14, 2025 | Buy | $0.97 | 28,157 | $27,244.71 | 250,674 | |
| Dizon Romeo R | IRIX | Chief Financial Officer | Sep 12, 2025 | Buy | $1.37 | 1,450 | $1,974.50 | 88,736 | |
| Dizon Romeo R | IRIX | Chief Financial Officer | Sep 11, 2025 | Buy | $1.35 | 1,250 | $1,682.20 | 88,736 | |
| Dizon Romeo R | IRIX | Chief Financial Officer | Sep 10, 2025 | Buy | $1.35 | 1,500 | $2,010.00 | 88,736 |
IRIX Breaking Stock News: Dive into IRIX Ticker-Specific Updates for Smart Investing
See how IRIX stacks up against similar companies in the market
Enhance your trading experience with our free tools
The information presented on this page, "IRIX IRIDEX Corporation - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.